Prognostic Significance of Fatty Liver Disease in Bariatric Patients

Recruiting N/A Interventional Study
Non-Alcoholic Fatty Liver Disease Metabolic Encephalopathy Obesity, Morbid Non-alcoholic Steatohepatitis
No Placebo Group Every participant receives an active treatment — no one gets a placebo.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 and older
Sex
Any
Study type
Interventional
Purpose
Diagnostic
Participants needed
1,200 (estimated)
Sponsor
Esbjerg Hospital - University Hospital of Southern Denmark · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
Prospective non-randomized intervention case control study on patients with a BMI \> 35. The intervention group/cases (n=600) is comprised of bariatric patients who undergo bariatric surgery and the control group (n=600) of age, weight and comorbidity matched patients who choose not to undergo bariatric surgery. The overall aim is to examine prevalence of the spectrum of fatty liver disease (NAFLD…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria case group: * Age \> 18 years * BMI \>35 kg/m2 and referred for bariatric surgery at Hospital of South West Jutland, Denmark * Able to give written informed consent. Inclusion criteria control group: * Age \> 18 years * BMI \>35 kg/m2 with no wish to undergo bariatric surgery. …
Contacts

Mette M Lauridsen, MD PhD

4579182000

mette.enok.munk.lauridsen@rsyd.dk

CONTACT